Episode Details

Medtronic Q4 FY2026 earnings deep-dive — conversational walkthrough of the strongest annual top-line growth in a decade, the GLP-1 diabetes overhang, Hugo robotics vs ISRG, and the pulsed-field ablation (PFA) competitive race. THE NUMBERS — Q4 FY2026 (As of close, 2026-06-03) - Revenue: $9.807B (+9.9% YoY) — best annual growth in 10 years - Non-GAAP EPS: $1.55 (vs $1.54 est, beat by $0.01) - GAAP EPS: ~$0.96 (reflects non-cash amortization of acquisition intangibles) - Gross Margin: 65.3% (+60bps YoY) - Operating Margin: 19.1% (+100bps YoY) - Free Cash Flow: $2.085B (165% FCF conversion) SEGMENTS - Cardiovascular: $3.73B (+12% YoY) — PFA + TAVR leading - Neuroscience: $2.16B (+9.5% YoY) — DBS recovery - Medical Surgical: $2.65B (+8% YoY) — Hugo robotics early ramp - Diabetes: $1.28B (+3% YoY) — GLP-1 structural headwind GUIDANCE - FY2027 Revenue: $33.2-$33.6B (~5.5% organic growth); Non-GAAP EPS: $5.85-$5.95 - ~$200M tariff headwind embedded in guidance WALL STREET - 15 Strong Buy / 2 Buy / 13 Hold / 0 Sell -> BUY - Median PT: $105.76 (range $84 - $121) THESIS Medtronic is a dividend aristocrat at a decade-low valuation with the first tangible evidence of organic growth reacceleration. The thesis for HOLD at current prices: accumulate toward the $72 add-zone, wait for GLP-1 diabetes narrative to stabilize, and own the valuation re-rating when the Street finally credits the new growth profile. Bull: Cardiovascular PFA adoption, Hugo surgical robotics international rollout, Neuroscience DBS market expansion -- combined can sustain 8-10% organic growth and drive margin expansion to mid-20% operating margin. Risk: GLP-1 structural diabetes volume erosion is not a 1-2 quarter story. If the diabetes segment declines 5-10% annually for 3+ years, MDT loses $200-400M in high-margin revenue. Combined with tariff headwinds and a slow Hugo ramp vs ISRG, the discount may persist. CAPITAL RETURNS - 47 consecutive years of dividend increases (Dividend Aristocrat) - Dividend raised to $0.72/quarter (June 3, 2026) - $5B buyback authorization active DISCLAIMER This is for informational and educational purposes only. Not financial advice. Compiled with frontier AI research models. All scripts are AI-generated. Charged Alpha does not have a position in MDT. #MDT #Medtronic #earnings #medicaldevices #investing #stocks #ChargedAlpha #diabetes #GLP1 #cardiovascular #robotics